Per- and polyfluoroalkyl substances (PFAS) have earned the moniker "forever chemicals" due to their extreme persistence in the environment. Their detection is crucial for protecting public health and the environment as these synthetic compounds continue to pose significant challenges worldwide. This comprehensive exploration examines why PFAS detection matters, current detection methods, and future directions in addressing PFAS contamination.<h3>Understanding PFAS and Their Health Impacts</h3>PFAS are a class of synthetic organic compounds with diverse structures, properties, and uses. Despite their diversity, all PFAS contain perfluoroalkyl moieties that are extremely resistant to environmental and metabolic degradation [1]. This high persistence is a defining characteristic that makes PFAS management particularly challenging.<h3>Documented Health Effects</h3>Current scientific research has linked PFAS exposure to numerous adverse health outcomes:<ul><li>Reproductive effects including decreased fertility and increased high blood pressure in pregnant women [8]</li><li>Developmental effects in children such as low birth weight, accelerated puberty, and behavioral changes [8]</li><li>Reduced immune system function, including decreased vaccine response</li><li>Interference with natural hormones and endocrine disruption</li><li>Increased cholesterol levels and obesity risk</li><li>Increased risk of several cancers, including prostate, kidney, testicular, oral cavity/pharynx, brain, and endocrine cancers [3]</li></ul>A 2023 study linked PFAS-contaminated water with up to a 33% increase in cancer incidence in affected areas [3]. The study compared regions with elevated PFAS levels to cancer data from the National Cancer Institute, finding higher incidences of various cancers after controlling for factors like smoking and obesity.<h3>Environmental Persistence and Contamination</h3>The extreme persistence of PFAS represents a fundamental concern for environmental management. PFAS are considered the most environmentally persistent substances among organic chemicals [7]. This persistence means that even if all PFAS uses were immediately phased out, existing contamination would continue to affect ecosystems and water supplies for generations.A 2023 study at a military fire training site estimated that PFAS contamination will persist for centuries without remediation [7]. The research found that terminal PFAS still exceed regulatory limits by 2000-fold decades after aqueous film-forming foam (AFFF) use ceased, with precursors accounting for around half of the extractable organofluorine across years.<h3>Current Detection Methods</h3><h4>EPA Standardized Methods</h4>The Environmental Protection Agency (EPA) has developed several standardized methods for PFAS detection, each with specific applications and capabilities:<h5>EPA Method 533</h5><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/epa-533-drying-down-pfas-samples-after-spe">EPA Method 533</a> focuses on "short chain" PFAS with carbon chain lengths of C4 to C12. Released in December 2019, this method complements Method 537.1 and includes several key features:<ul><li>Uses isotope dilution quantification approach with extracted internal standards, which reduces overall analytical uncertainty</li><li>Employs weak anion exchange solid phase extraction cartridges as opposed to polystyrene divinylbenzene used in 537.1</li><li>Can analyze 25 PFAS compounds, including additional short-chain PFAS that were not apart of Method 537.1</li><li>Allows for longer holding times: 28 days to extraction and 28 days to analyze (compared to 14 days to extraction in Method 537.1)</li><li>Uses ammonium acetate as a preservative (versus Trisma in Method 537.1) [1]</li></ul><h5>EPA Method 537/537.1</h5><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/sample-concentration-epa-method-537-pfas-determination">EPA Method 537 </a>was first published in 2009 for the determination of 14 PFAS in drinking water [6]. It was later updated to Method 537.1 in 2018 (with editorial updates in 2020) to expand its capabilities:<ul><li>Uses<a target="_blank" rel="noopener noreferrer" href="https://www.organomation.com/what-is-solid-phase-extraction-spe"> solid phase extraction (SPE) </a>and<a target="_blank" rel="noopener noreferrer" href="https://www.organomation.com/preparing-samples-for-lc-ms/ms-analysis"> liquid chromatography/tandem mass spectrometry (LC-MS/MS)</a></li><li>Method 537.1 expanded detection to 18 PFAS compounds, including HFPO-DA (one component of GenX technology)</li><li>Utilizes styrene-divinylbenzene (SDVB) media for extraction</li><li>Requires samples to be extracted within 14 days and analyzed within 28 days</li><li>Methanol is used to elute the extracts. This should then be reconstituted with a 96:4 methanol:water mixture [1]</li></ul>Together, Methods 533 and 537.1 can detect a total of 29 unique PFAS compounds in drinking water and are approved for monitoring under the fifth Unregulated Contaminant Monitoring Rule (UCMR 5) and the PFAS National Primary Drinking Water Regulation [1] [3].<h5>EPA Method 1633</h5><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/preparing-diverse-sample-matrices-for-epa-method-1633">EPA Method 1633</a>, released in 2024, represents a significant advancement in PFAS analysis:<ul><li>Developed for the analysis of 40 PFAS compounds in various matrices, including surface water, groundwater, wastewater, soil, biosolids, sediment, landfill leachate, and fish tissue</li><li>Expands beyond the drinking water focus of Methods 533 and 537.1</li><li>Provides a standardized approach that may replace modified drinking water methods (i.e., modified EPA 537) that were previously used for non-drinking water matrices [1]</li></ul><h4>Conventional Analytical Techniques</h4>The gold standard for PFAS analysis involves chromatographic techniques coupled with mass spectrometry:<ul><li>Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) is the most widely used method for PFAS analysis, offering high sensitivity and specificity [1]</li><li>High-Resolution Mass Spectrometry (HRMS) allows for rapid detection and identification of PFAS species at very low concentrations [5]</li></ul>These techniques can detect PFAS at parts per trillion (ppt) levels, which is essential given the low concentrations at which PFAS can cause health effects [1]. However, these methods require sophisticated equipment, specialized training, and significant financial resources, making them inaccessible in many regions, particularly in developing countries.<h4>Emerging Detection Technologies</h4>Several innovative approaches are being developed to address the limitations of conventional methods:<ul><li>Electrochemical biosensors using modified electrodes have shown promise for selective PFAS detection with low detection limits [2]</li><li>Surface-Enhanced Raman Spectroscopy (SERS) uses metallic nanoparticles and can be made into a portable method for on-site testing [1]</li><li>Molecular imprinted polymers (MIPs) offer thermal and physical stability, reusability, and low-cost synthesis for PFAS detection [6]</li></ul>These emerging technologies aim to provide more accessible, field-deployable, and cost-effective alternatives to traditional laboratory-based methods.<h3>Challenges in PFAS Detection</h3><h4>Analytical Challenges</h4>Detecting PFAS presents several technical challenges:<ul><li>The ubiquity of PFAS in laboratory equipment and accessories can lead to background contamination when measuring at parts-per-trillion levels [1]</li><li>Many components in liquid chromatographs, mass spectrometers, and solid-phase extraction systems contain materials that can leach PFAS compounds [9]</li><li>The vast number of PFAS (thousands of compounds) makes comprehensive detection difficult, as analytical standards are only available for a small subset [1]</li><li>Complex matrices like food and environmental samples require sophisticated sample preparation techniques</li></ul><h4>Global Disparities in Detection Capabilities</h4>Access to PFAS detection technology varies significantly worldwide:<ul><li>Many developing regions, particularly in Africa, lack adequately equipped laboratories with the necessary instrumentation to detect and measure PFAS</li><li>There is often a scarcity of qualified professionals with experience in PFAS analysis in these regions</li><li>The high cost of acquiring and maintaining sophisticated analytical instruments presents a substantial obstacle to conducting extensive PFAS investigations in resource-limited settings [1]</li><li>Competing priorities such as infectious diseases, poverty, and food security often divert attention and resources from environmental pollutants like PFAS</li></ul><h4>Regulatory Landscape and Compliance</h4>The regulatory framework for PFAS is evolving rapidly worldwide:<ul><li>The EPA finalized Section 8(a)(7) of the Toxic Substances Control Act in September 2024, requiring manufacturers and importers to report on their use of PFAS since 2011 [10]</li><li>Electronic reporting for PFAS will open on July 11, 2025, with final reporting deadlines in 2026</li><li>Companies must report detailed information including chemical identity, production volumes, industrial and consumer products, worker exposure, and disposal methods [10]</li></ul>These regulations are driving demand for more effective and accessible PFAS detection methods to ensure compliance and protect public health.<h3>Future Directions in PFAS Detection</h3><h4>Technological Advancements</h4>The future of PFAS detection lies in developing more accessible, sensitive, and comprehensive methods:<ul><li>Non-targeted screening methods that can identify unknown PFAS compounds without requiring analytical standards for each specific compound</li><li>Total fluorine analysis techniques like Adsorbable Organic Fluorine and Total Oxidizable Precursor Assay that can quantify the presence of fluorine atoms within a sample [1]</li><li>Portable sensors and field-deployable technologies that enable on-site monitoring and rapid response to contamination events</li><li>AI-driven solutions that can improve data analysis and interpretation for complex PFAS mixtures</li></ul><h4>Collaborative Approaches</h4>Addressing the global challenge of PFAS detection requires coordinated efforts:<ul><li>International partnerships between researchers in developed and developing regions to enhance expertise and capacity building</li><li>Standardization of analytical methods to ensure consistency and comparability of results across different laboratories and regions</li><li>Open data sharing and collaboration across countries to leverage collective knowledge and resources</li><li>Integration of PFAS monitoring into broader environmental and public health surveillance systems</li></ul><h3>Conclusion</h3>The detection of PFAS is not merely a technical challenge but a critical public health and environmental imperative [1]. As these "forever chemicals" continue to persist in our environment, developing effective, accessible, and comprehensive detection methods becomes increasingly important. By advancing detection technologies, strengthening regulatory frameworks, and fostering global collaboration, we can better understand, monitor, and ultimately mitigate the impacts of PFAS contamination.The EPA's standardized methods (533, 537.1, and 1633) provide crucial tools for monitoring PFAS in various environmental matrices, but continued innovation is needed to address the full spectrum of PFAS compounds and to make detection more accessible globally [1] [6]. The path forward requires sustained investment in research and development, capacity building in resource-limited settings, and a commitment to environmental justice that ensures all communities have access to the tools and information needed to protect themselves from PFAS exposure. Only through such comprehensive approaches can we hope to address the complex challenges posed by these persistent pollutants.Be sure to check out our other installments of our&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/introducing-our-environmental-contaminants-series-making-sense-of-the-alphabet-soup">Environmental Contaminant Series</a>&nbsp;covering&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/the-importance-of-detecting-persistent-organic-pollutants-pops">Persistent Organic Pollutants (POPs)</a>,&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/the-importance-of-detecting-polycyclic-aromatic-hydrocarbons-pahs">Polycyclic Aromatic Hydrocarbons (PAHs)</a>,&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/the-importance-of-detecting-semi-volatile-organic-compounds-svocs">Semi-Volatile Organic Compounds (SVOCs)</a>, and <a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/the-importance-of-detecting-polychlorinated-biphenyls-pcbs">Polychlorinated Biphenyls (PCBs)</a>.

The Importance of Detecting Per- and Polyfluoroalkyl Substances (PFAS)

Scientists at CEITEC Brno University of Technology have developed microscopic robots that could one day accelerate beer production and simplify food quality control. The magnetically controlled biobots can actively mix liquids during fermentation, speed up the process, and separate themselves from the finished product once fermentation is complete. The results of the research, carried out by Professor Martin Pumera’s team, were published in the journal ACS Nano.“When people hear the word ‘robot’ today, they often imagine an electronic device. In reality, however, a robot can be any system capable of autonomously performing a specific task,” explains Martin Pumera of CEITEC Brno University of Technology.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Mikroroboti_z_CEITEC_mohou_urychlit_vyrobu_piva_i_kontrolu_kvality_potravin_7d9ff82875.jpeg" alt="CEITEC BUT/Jakub Rozboud: CEITEC Microrobots Could Speed Up Beer Production and Food Quality Control: Martin Pumera in his lab at CEITEC BUT." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Mikroroboti_z_CEITEC_mohou_urychlit_vyrobu_piva_i_kontrolu_kvality_potravin_7d9ff82875.jpeg 235w," sizes="100vw" width="1600" height="1067">The research team created so-called biobots—biohybrid microrobotic capsules containing brewer’s yeast and magnetic nanoparticles. When the yeast produces carbon dioxide during fermentation, the resulting bubbles cause the biobots to move up and down through the liquid. This naturally mixes the contents of the vessel and makes fermentation more efficient. Compared with conventional static particles, the biobots can therefore accelerate chemical processes that are important in food production.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Mikroroboti_z_CEITEC_mohou_urychlit_vyrobu_piva_i_kontrolu_kvality_potravin_4_af5fd4611f.jpg" alt="CEITEC BUT/Martin Pumera's archive: CEITEC Microrobots Could Speed Up Beer Production and Food Quality Control: Hematite microrobot (image for illustrative purposes)." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Mikroroboti_z_CEITEC_mohou_urychlit_vyrobu_piva_i_kontrolu_kvality_potravin_4_af5fd4611f.jpg 209w," sizes="100vw" width="1600" height="1192">Another major advantage of the technology is that the biobots can be easily separated from the finished beverage. Thanks to the magnetic particles they contain, they can be controlled with a magnetic field and removed once fermentation is complete, eliminating the need for additional filtration. The researchers also demonstrated that the biobots can be reused over several production cycles.“Unlike conventional static particles, microrobots actively move throughout the entire volume of the liquid, allowing them to cover a larger area and make the whole process more efficient. At the same time, they also facilitate the automation of production,” adds Martin Pumera. The team is currently discussing potential applications of the technology with a major European brewery.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Mikroroboti_z_CEITEC_mohou_urychlit_vyrobu_piva_i_kontrolu_kvality_potravin_3_e8e5a3a55a.jpg" alt="CEITEC BUT/Martin Pumera's archive: CEITEC Microrobots Could Speed Up Beer Production and Food Quality Control: g-C₃N₄ microrobots (image for illustrative purposes)." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Mikroroboti_z_CEITEC_mohou_urychlit_vyrobu_piva_i_kontrolu_kvality_potravin_3_e8e5a3a55a.jpg 158w," sizes="100vw" width="1476" height="1460">Martin Pumera’s group has long been exploring the use of microrobots and advanced materials in the food industry. In the past, for example, the team developed a flexible sensor for smart packaging capable of detecting spoiled fish. The new biobots therefore represent another step towards more advanced methods of food quality and safety control.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Mikroroboti_z_CEITEC_mohou_urychlit_vyrobu_piva_i_kontrolu_kvality_potravin_2_75c7fed958.jpeg" alt="CEITEC BUT/ACS Nano: CEITEC Microrobots Could Speed Up Beer Production and Food Quality Control: ACS Nano - cover featuring article by Martin Pumera et al." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Mikroroboti_z_CEITEC_mohou_urychlit_vyrobu_piva_i_kontrolu_kvality_potravin_2_75c7fed958.jpeg 117w," sizes="100vw" width="1600" height="2128">

 CEITEC Microrobots Could Speed Up Beer Production and Food Quality Control 

In this episode of ‪ChromatographyTalk‬, ‪Organomation‬ General Manager David Oliva sits down with Michelle Taylor, Editor-in-Chief of LabCompare, to go behind the scenes of their groundbreaking two-part documentary series on PFAS (per- and polyfluoroalkyl substances).The conversation kicks off with a startling revelation: many of the world’s leading PFAS experts have completely stopped eating seafood due to high contamination levels discovered during testing. From there, we dive deep into the technical and regulatory challenges facing today's analytical laboratories.<h4>In this episode, we discuss:</h4><ul><li>The Laboratory Throughput Crisis: Why labs are currently "overwhelmed with samples" and how tiered testing—using single quad instruments for screening before moving to triple quads—is helping to manage capacity without sacrificing sensitivity.</li><li>The Battle Against Background Contamination: Why PTFE-free (PFAS-free) laboratory equipment is no longer optional when trying to detect "forever chemicals" at the parts-per-trillion and parts-per-quadrillion levels.</li><li>Complex Matrices (Seafood &amp; Packaging): The technical hurdles of analyzing high-lipid samples like fish and the rising demand for migration testing as states like Rhode Island begin to phase out PFAS in food packaging.</li><li>Global Regulatory Shifts: A look at the "dual compliance model" required for labs supporting international exporters, especially with the European Union’s stricter enforcement compared to the U.S. monitoring approach.</li><li>The "Grand Challenge" of Unknowns: How EPA Method 1621 (Total Organic Fluorine) is helping labs close the mass balance gap and why the next generation of bench chemists must embrace *AI and data science* to manage the massive datasets generated by high-resolution mass spectrometry.</li><li>PFAS Destruction vs. Remediation: &nbsp;The promising (and problematic) methods for breaking the carbon-fluorine bond, and why incineration may inadvertently be spreading shorter-chain PFAS into the air.</li></ul>Whether you are a lab manager looking to future-proof your workflow or a chemist navigating the ever-evolving landscape of EPA Method 1633, this episode provides essential insights into the most pressing environmental crisis of our time.<h3>Video Transcription</h3><h4>Michelle Taylor: PFAS Testing Is Becoming a Much Bigger Analytical Challenge</h4>PFAS analysis has rapidly evolved from a specialized environmental testing problem into a much broader challenge involving drinking water, food, packaging, laboratory contamination, international regulation, data analysis, and even destruction technologies. In an interview with Michelle Taylor, Editor-in-Chief of Labcompare, the discussion explored what laboratories are learning from the latest PFAS research—and why the analytical demands are likely to continue growing.Taylor leads editorial content for Labcompare, an online resource covering analytical laboratory instrumentation, products, and scientific developments. Among the projects she considers particularly important are two long-form documentaries produced by Labcompare examining per- and polyfluoroalkyl substances (PFAS), first through drinking water and subsequently through food.The documentaries brought together subject-matter experts working across PFAS analysis and exposed some of the practical realities laboratories now face: rapidly changing regulations, extremely low detection limits, complex matrices, contamination risks, and sample volumes that can overwhelm laboratory capacity.<h4>From drinking water to seafood</h4>One of the most memorable findings for Taylor came during production of the second documentary, which focused on PFAS in food.Several experts interviewed for the project told her they had stopped eating seafood, in some cases many years earlier, because of concerns surrounding contamination. For Taylor, the consistency and immediacy of those responses illustrated how closely analytical research can intersect with everyday decisions.Seafood also demonstrates why PFAS testing can become analytically difficult.Fish and other high-lipid samples require effective extraction to release the analytes, followed by rigorous cleanup to remove fats. According to the experts Taylor interviewed, the cleanup step is particularly critical because residual lipids can damage LC columns and create severe matrix interferences.Laboratories are therefore using approaches such as enhanced matrix removal and carbon- or silica-based sorbents to reduce the lipid content of extracts before instrumental analysis. The goal is not simply obtaining sufficient recovery, but producing an extract clean enough to maintain analytical performance and laboratory throughput.<h4>How laboratories are handling the PFAS sample burden</h4>The analytical sensitivity now required for PFAS testing presents another challenge: laboratories may need to measure compounds at parts-per-trillion levels while processing growing numbers of samples.Automation has therefore become increasingly important, particularly during sample preparation, where repetitive manual procedures can otherwise create a major bottleneck.Taylor also described a tiered analytical strategy being used by some laboratories. A less demanding measurement can first be used for screening, while samples generating a positive result are subsequently transferred to a more sensitive platform, such as triple-quadrupole mass spectrometry, for confirmation and quantitation.This type of workflow can help laboratories concentrate their highest-performance instrumentation on the samples that actually require it rather than applying the most intensive analysis to every incoming sample.The broader principle is likely to become increasingly important as PFAS testing expands: laboratories must find ways to increase throughput without sacrificing the sensitivity demanded by regulatory methods.<h4>When the laboratory itself becomes a source of PFAS</h4>At trace concentrations, contamination introduced during sample preparation or measurement can become comparable to the concentration being determined.This makes the materials used throughout the analytical workflow particularly important.Taylor emphasized that PFAS laboratories must maintain continuous awareness of potential contamination from solvents, water, tubing, containers, and other laboratory components. Equipment containing fluoropolymers such as PTFE may be problematic in certain PFAS workflows because background contamination can contribute to false positives or elevated blanks.As detection limits move lower, dedicated PFAS-compatible or fluoropolymer-free laboratory equipment becomes increasingly valuable.Taylor described manufacturers offering clearly identified PFAS-free configurations as an important response to this problem. Rather than forcing laboratories to investigate the material composition of each component individually, dedicated configurations can simplify method implementation and reduce uncertainty about potential background sources.For laboratories already dealing with demanding workflows and large sample loads, eliminating potential contamination before it occurs can save considerable troubleshooting time.<h4>Food packaging could drive the next major wave of testing</h4>PFAS concerns are not limited to the food itself.The interview also examined food-contact materials, including takeout containers and other packaging from which PFAS may migrate into food. State-level restrictions in the United States are already beginning to affect the materials manufacturers can use.For contract laboratories, this creates the possibility of another significant increase in demand for compliance and migration testing.Taylor’s recommendation is straightforward: laboratories should follow proposed regulations before they become final.Waiting until a new requirement takes effect can leave a laboratory simultaneously trying to acquire instrumentation, establish methods, train staff, and respond to customer demand. Monitoring regulatory agencies, scientific meetings, and industry discussions earlier gives laboratories time to prepare analytical capabilities before the testing requirement becomes urgent.She expects PFAS restrictions in food packaging to continue developing first through a patchwork of individual state regulations. Once a sufficient number of states adopt restrictions, however, the economics may increasingly encourage suppliers to move toward PFAS-free materials regardless of whether every jurisdiction requires them.A national standard could eventually follow that transition.<h4>One sample, two regulatory environments</h4>International food exporters face another complication: PFAS requirements are not necessarily the same between the United States and European Union.Taylor noted that laboratories serving both markets may effectively need to operate under a dual-compliance model.In the interview, she highlighted EU requirements targeting specific PFAS—including PFOS, PFOA, PFNA, and PFHxS—at very low concentrations in certain foods, while the U.S. approach has historically involved a different combination of monitoring programs, evolving compound lists, and import-related requirements.For laboratories supporting international customers, this means more than simply selecting a different reporting limit.Different markets may require different target lists, methods, documentation, auditing, and compliance procedures. Laboratories therefore need analytical platforms capable of ultratrace measurements while also maintaining the operational flexibility to support multiple regulatory frameworks.That additional complexity also carries a practical cost: performing different protocols for different jurisdictions means more staff time, additional workflow management, and potentially greater instrument demand.<h4>Total fluorine screening can help laboratories decide what to analyze next</h4>Targeted LC-MS/MS methods are highly sensitive, but they only measure compounds included in the analytical panel.This creates an important question: what about fluorinated substances that are present but are not included in the targeted method?The interview discussed EPA Method 1621, which uses a broader fluorine-based screening approach. Taylor described this type of measurement as useful for helping laboratories assess the gap between compounds captured by targeted LC-MS/MS methods and the broader amount of organofluorine present in a sample.Such screening can also become part of a tiered workflow.For applications such as food packaging, laboratories could initially use a broader fluorine measurement to determine whether a sample warrants further investigation. Positive or suspicious samples could then move to more selective and sensitive targeted analysis for identification and quantitation.Non-targeted high-resolution mass spectrometry can add another layer by revealing compounds outside conventional target lists.Together, these approaches create a funnel from broad screening toward increasingly detailed characterization rather than attempting the most comprehensive analysis on every sample from the outset.<h4>PFAS analysis is becoming a data problem too</h4>High-resolution mass spectrometry can generate enormous datasets containing signals from large numbers of known and unknown compounds.As a result, Taylor believes the role of the analytical chemist is changing.Strong laboratory skills remain essential, but scientists increasingly need data literacy as well. Understanding complex datasets, working with advanced software, and interacting effectively with artificial intelligence and machine-learning tools are becoming important parts of modern analytical work.Taylor does not see this change primarily as replacing scientific expertise.Instead, she compares it with earlier laboratory automation: repetitive or technically demanding tasks can increasingly be handled by software, allowing scientists to spend more time interpreting results and making decisions.AI may also make sophisticated analytical information more accessible. A less experienced mass spectrometry user could potentially receive explanations of complex data through software capable of presenting results in natural language, reducing dependence on a single specialist being immediately available.There is another potential advantage beyond speed.Machine-learning systems can recognize patterns across large datasets that may be difficult or impossible for an individual scientist to detect manually. As analytical datasets become larger and multidimensional, that pattern-recognition capability could become increasingly valuable.<h4>Finding PFAS is only the first half of the problem</h4>For years, much of the PFAS discussion has focused on answering two questions:<ul><li>Are PFAS present, and how much is there?</li></ul>The next challenge is considerably harder: how do we actually remove or destroy them?Taylor described this as an expanding research field that will increasingly involve analytical laboratories.The strength of the carbon-fluorine bond makes PFAS destruction difficult. Some treatment approaches seek to break this bond and achieve complete defluorination, but incomplete destruction can create another analytical problem.For example, thermal treatment may transform longer-chain PFAS into shorter-chain fluorinated compounds rather than eliminating them completely. Those products may then enter another environmental compartment, including atmospheric emissions.Consequently, laboratories studying PFAS destruction must do more than measure disappearance of the original compound. They also need to determine whether fluorinated transformation products or other byproducts remain.Analytical chemistry therefore has two roles: monitoring PFAS contamination and demonstrating whether remediation technologies truly destroy the substances they are intended to remove.<h4>The PFAS problem is expanding beyond water and food</h4>The first two Labcompare documentaries focused primarily on water and food, two matrices already receiving substantial regulatory and public attention.But Taylor does not expect the story to end there.If Labcompare produces another PFAS documentary, she sees PFAS in air as a likely subject. Discussions with experts during earlier filming repeatedly raised atmospheric contamination, including both direct environmental occurrence and emissions potentially associated with treatment or destruction processes.The progression illustrates how quickly the PFAS field is expanding.Drinking water regulation accelerated analytical development. Food testing introduced more difficult matrices and new exposure pathways. Packaging is creating another compliance challenge. Environmental remediation raises questions about destruction products. Atmospheric monitoring could become another significant frontier.For laboratories already working with chromatography and mass spectrometry, Taylor’s message is essentially to be prepared—even organizations that do not currently consider themselves “PFAS laboratories” may eventually become involved.<h4>An analytical field that is still changing rapidly</h4>Perhaps the strongest theme running through the interview is that PFAS analysis has no fixed endpoint yet.Methods continue to evolve. Regulations change. Target compound lists expand. Instrument sensitivity improves. Laboratories discover new sources of background contamination, while researchers identify additional exposure pathways and investigate new destruction technologies.Taylor compares the situation to earlier periods of rapid analytical development, such as the evolution of forensic DNA analysis: each technological advance reveals more information, which in turn creates new questions and new analytical requirements.That makes preparation particularly important.Laboratories cannot predict every future regulation, but they can follow proposed requirements, develop flexible workflows, invest in contamination control and data capabilities, and understand how their existing chromatography and mass spectrometry expertise could be applied to emerging PFAS challenges.The analytical problem is no longer simply detecting a group of “forever chemicals.”It is becoming a much larger question of how we identify them, quantify them, prevent contamination during analysis, understand their movement through food and the environment, comply with evolving regulations, and ultimately prove that they have actually been destroyed.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

PFAS in Water, Food & Packaging: Michelle Taylor on the "Forever Chemicals" Documentary Series

Article

Scientists

Environment

Food

Water

Interview

Science and research

Video

Since its establishment in 2011, CEITEC has quickly developed into a cutting-edge infrastructure for research which performs highly alongside the best institutes in Europe. Among the main priorities of CEITEC are the promotion of a motivating and dynamic international scientific environment, the provision of state-of-the-art research infrastructure, and the policy of open communication and equal opportunities.

CEITEC

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Follistatin Analysis

Targeted HPLC analysis of follistatin in lyophilised vials and raw API powders, confirming identity and determining the amount of the compound.

The Follistatin Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of follistatin in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). Follistatin is a protein rather than a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About Follistatin</h4>Follistatin is a naturally occurring glycoprotein that binds activin with high affinity and regulates its biological activity. It also interacts with other members of the TGF-β superfamily and has been studied in connection with processes including muscle growth, reproduction, and tissue regulation.Follistatin occurs in several molecular forms and is widely used as a research target in studies of activin signalling and related biological pathways.<h4>Key Features</h4><ul><li>Targeted identification and quantification of follistatin</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powder</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Follistatin</li><li>Testing method: HPLC</li><li>Result format for lyophilisate: mg per vial</li><li>Alternative result format: Purity in % (m/m)</li><li>Minimum sample amount for lyophilisate: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powder: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>Follistatin is a protein rather than a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products?search=Endotoxin">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

L-Carnitine analysis

Targeted HPLC analysis of L-carnitine in tablets, capsules, liquid samples, and raw API powders, confirming identity and determining content.

The L-Carnitine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of L-carnitine in oral dosage forms, liquid samples, and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for tablets and capsules, with results reported in milligrams per tablet or capsule, as well as liquid samples, with results reported in mg/ml. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m).<h4>About L-Carnitine</h4>L-carnitine is a naturally occurring compound involved in mitochondrial fatty-acid metabolism. Its primary biological role is to transport long-chain fatty acids across the inner mitochondrial membrane, enabling their subsequent beta-oxidation and use as a source of cellular energy.In the human body, L-carnitine is obtained from dietary sources and can also be synthesised endogenously from the amino acids lysine and methionine. It is concentrated particularly in tissues with high energy demands, such as skeletal and cardiac muscle, and is also used therapeutically in the management of primary and secondary carnitine deficiencies.<h4>Key Features</h4><ul><li>Targeted identification and quantification of L-carnitine</li><li>Suitable for tablets, capsules, liquid samples, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for liquid samples reported in mg/ml</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum liquid sample amount of 0.5–1 ml</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: L-Carnitine</li><li>CAS number: 541-15-1</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for liquid samples: mg/ml</li><li>Alternative result format: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for liquid samples: 0.5–1 ml</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for L-carnitine. It does not automatically screen the sample for related carnitine derivatives, contaminants, or undeclared substances unless an additional screening service is ordered.</li><li>Purity reporting in % (m/m) is available as an alternative result format.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Lipo-C (L-Carnitine content, L-Arginine Content, B12 Content, Total Solids)

Lipo-C analysis determines L-carnitine, L-arginine, vitamin B12, and total solids content, with target compounds analysed by HPLC.

The Lipo-C Analysis is a targeted laboratory test designed to determine the content of L-carnitine, L-arginine, and vitamin B12, together with the total solids content of a Lipo-C sample.The target compounds are analysed by HPLC, with results reported in mg/ml. Total solids provide an additional measure of the overall amount of solid material present in the sample, helping assess the composition of the formulation beyond the individual quantified compounds.<h4>About the Analyzed Compounds</h4>L-carnitine is involved in mitochondrial fatty-acid metabolism and facilitates the transport of long-chain fatty acids into mitochondria for beta-oxidation. L-arginine is an amino acid involved in several metabolic pathways and serves as a precursor for nitric oxide synthesis.Vitamin B12 (cobalamin) is an essential micronutrient that functions as a cofactor for enzymes involved in important metabolic reactions and DNA synthesis.Total solids represent the overall solid material present in a sample, including dissolved and suspended material. This measurement complements the targeted determination of L-carnitine, L-arginine, and vitamin B12.<h4>Key Features</h4><ul><li>Targeted determination of L-carnitine, L-arginine, and vitamin B12</li><li>Total solids determination included</li><li>Analysis of target compounds by HPLC</li><li>Results reported in mg/ml</li><li>Suitable for Lipo-C liquid samples</li><li>Minimum sample amount of one whole unopened vial</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compounds: L-Carnitine, L-Arginine, Vitamin B12</li><li>Additional determination: Total Solids</li><li>Testing method: HPLC</li><li>Result format: mg/ml</li><li>Minimum sample amount: One whole unopened vial</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically designed to determine L-carnitine, L-arginine, vitamin B12, and total solids in a Lipo-C sample.</li><li>The analysis does not automatically screen the sample for other active compounds, ingredients, contaminants, or undeclared substances.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

NAD+ analysis

Targeted HPLC analysis of NAD+ in tablets, capsules, and raw API powders, confirming compound identity and determining its amount.

The NAD+ Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of NAD+ in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for tablets and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). NAD+ is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About NAD+</h4>NAD+ (nicotinamide adenine dinucleotide) is the oxidized form of an essential cellular coenzyme involved in redox reactions and energy metabolism. It accepts electrons during metabolic reactions and is converted to its reduced form, NADH, which participates in cellular energy production.NAD+ is present throughout cellular metabolism and plays an important role in maintaining the balance between oxidation and reduction reactions required for normal cellular function.<h4>Key Features</h4><ul><li>Targeted identification and quantification of NAD+</li><li>Suitable for tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: NAD+</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: m/m purity in % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>NAD+ is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for NAD+. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances unless an additional screening service is ordered.</li><li>The stated detection limit cutoff is less than 1/20 of the usual dosage per vial.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

NMN (Nikotinamid mononukleotid) analysis

Targeted HPLC analysis of NMN in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The NMN Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of nicotinamide mononucleotide (NMN) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m).<h4>About NMN</h4>Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and an intermediate in the biosynthesis of nicotinamide adenine dinucleotide (<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2546">NAD+</a>). NMN is converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNATs).NAD+ is an essential cellular coenzyme involved in energy metabolism, redox reactions, and numerous enzymatic processes. NMN has therefore been studied as an NAD+ precursor in both preclinical and clinical research.<h4>Key Features</h4><ul><li>Targeted identification and quantification of NMN</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Nicotinamide mononucleotide</li><li>Other name: NMN</li><li>CAS number: 1094-61-7</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>NMN is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for NMN. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Sibutramine analysis

Targeted HPLC analysis of sibutramine in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Sibutramine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of sibutramine in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Sibutramine</h4>Sibutramine is a serotonin-noradrenaline reuptake inhibitor (SNRI) that was formerly used as a weight-management medicine. By inhibiting the reuptake of serotonin and noradrenaline, it affects neurotransmitter signalling involved in appetite and satiety.Sibutramine-containing medicines were suspended in the European Union and withdrawn from the U.S. market after clinical data showed an increased risk of serious cardiovascular events, including heart attack and stroke.<h4>Key Features</h4><ul><li>Targeted identification and quantification of sibutramine</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Sibutramine</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 4 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for sibutramine. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of sibutramine required for evaluation is 4 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li><li>Laboratory confirmation of sibutramine content should not be interpreted as confirmation that a product is safe for human use.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

SLU-PP-332 analysis

Targeted HPLC analysis of SLU-PP-332 in oral products, lyophilised vials, and raw API powders for identity confirmation and amount determination.

The SLU-PP-332 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of SLU-PP-332 in oral dosage forms, lyophilised vials, and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule, as well as lyophilised vials, with results reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). SLU-PP-332 is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About SLU-PP-332</h4>SLU-PP-332 is a synthetic research compound that acts as an agonist of the estrogen-related receptors ERRα, ERRβ, and ERRγ. These nuclear receptors regulate genes involved in mitochondrial metabolism, oxidative phosphorylation, and fatty-acid oxidation.SLU-PP-332 has been investigated primarily in preclinical studies. In mouse models, activation of ERR signalling by SLU-PP-332 has been associated with increased oxidative skeletal muscle fibres, improved exercise endurance, increased energy expenditure, and enhanced fatty-acid oxidation.<h4>Key Features</h4><ul><li>Targeted identification and quantification of SLU-PP-332</li><li>Suitable for pills, tablets, capsules, lyophilised vials, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for lyophilised samples reported in mg per vial</li><li>Alternative purity reporting in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: SLU-PP-332</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for lyophilised vials: mg per vial</li><li>Result format for raw API powders: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for lyophilised vials: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>SLU-PP-332 is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>For lyophilised SLU-PP-332 samples, the standard testing procedure uses water (H₂O) as the solvent. However, SLU-PP-332 is poorly soluble in water, and insoluble material may therefore be filtered out before analysis. Only dissolved material can be analysed.</li><li>DMSO can be selected as an alternative solvent because it dissolves SLU-PP-332 more effectively. However, samples dissolved in DMSO are not suitable for injection or human use. To use DMSO for the analysis, select the DMSO solvent option from the additional services.</li><li>This analysis is specifically intended for SLU-PP-332. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Solvent: DMSO</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

T3 analysis

Targeted HPLC analysis of T3 (liothyronine) in pills, tablets, capsules, and raw API powders, confirming identity and determining content.

The T3 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of T3 (liothyronine) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About T3</h4>T3, or triiodothyronine, is a naturally occurring thyroid hormone involved in the regulation of metabolism, growth, and energy utilisation. Liothyronine is the synthetic form of T3 used in pharmaceutical preparations.Liothyronine sodium is used clinically as thyroid hormone replacement therapy, particularly in the treatment of hypothyroidism. Cytomel is one of the established trade names for liothyronine sodium.<h4>Key Features</h4><ul><li>Targeted identification and quantification of T3</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: T3</li><li>Other names: Cytomel, Tiromel, liothyronine sodium</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 15 mcg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for T3. It does not automatically screen the sample for other thyroid hormones, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of T3 required for evaluation is 15 mcg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

T4 analysis

Targeted HPLC analysis of T4 (thyroxine) in pills, tablets, capsules, and raw API powders, confirming identity and determining content.

The T4 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of T4 (thyroxine) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in micrograms per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About T4</h4>T4, or thyroxine, is the major thyroid hormone produced and secreted by the thyroid gland. It plays an important role in the regulation of metabolism, growth, development, and energy utilisation. Much of circulating T4 is converted in peripheral tissues to the more biologically active thyroid hormone <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2550">T3</a>.Levothyroxine is the synthetic form of T4 and is widely used as thyroid hormone replacement therapy, particularly in the treatment of hypothyroidism.<h4>Key Features</h4><ul><li>Targeted identification and quantification of T4</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mcg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: T4</li><li>Other name: Thyroxine</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 15 mcg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mcg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for T4. It does not automatically screen the sample for other thyroid hormones, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of T4 required for evaluation is 15 mcg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Tesofensine analysis

Targeted HPLC analysis of tesofensine in oral products, lyophilised vials, and raw API powders for identity confirmation and amount determination.

The Tesofensine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of tesofensine in oral dosage forms, lyophilised vials, and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule, as well as lyophilised samples, with results reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). Tesofensine is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About Tesofensine</h4>Tesofensine is a centrally acting monoamine reuptake inhibitor that inhibits the reuptake of serotonin, noradrenaline, and dopamine. Its effects on these neurotransmitter systems have been investigated primarily in relation to appetite regulation and body weight.<h4>Key Features</h4><ul><li>Targeted identification and quantification of tesofensine</li><li>Suitable for pills, tablets, capsules, lyophilised vials, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for lyophilised samples reported in mg per vial</li><li>Alternative purity reporting in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Tesofensine</li><li>CAS number: 195875-84-4</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for lyophilised samples: mg per vial</li><li>Result format for raw API powders: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>Tesofensine is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for tesofensine. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances.</li><li>For raw API powders, at least 30 mg should be supplied in a sealed glass vial to minimise moisture absorption.</li><li>Purity reporting in % (m/m) is available for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Products from category Laboratory analyses - page 6

Related content

PFAS in Water, Food & Packaging: Michelle Taylor on the "Forever Chemicals" Documentary Series

CEITEC Microrobots Could Speed Up Beer Production and Food Quality Control

The Importance of Detecting Per- and Polyfluoroalkyl Substances (PFAS)